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Protocol
AbstrACt
Introduction Transoral robotic surgery (TORS) has been 
adopted in some parts of the world as an innovative 
approach to the resection of oropharyngeal tumours. The 
development, details and outcomes of early-to-later phase 
evaluation of this technique and the quality of evidence 
to support its adoption into practice have hitherto not 
been summarised. The aim of this review is to identify 
and summarise the early and later phase studies of, and 
evidence for, TORS and to understand how early phase 
studies report intervention development, governance 
procedures and selection and reporting of outcomes 
to optimise methods for using the Idea, Development, 
Exploration, Assessment, Long-term follow-up (IDEAL) 
framework for surgical innovation that informs evidence-
based practice. The protocol has been written in line with 
the Preferred Reporting Items for Systematic Review and 
Meta-Analysis Protocols checklist.
Methods and analysis Electronic searches in OVID SP 
versions of Medline and EMBASE, the Cochrane Central 
Register of Controlled Trials and the Cochrane Database 
of Systematic Reviews from the start of indexing to 30 
April 2017 will identify studies reporting TORS. At least two 
independent researchers will identify studies for inclusion. 
Two researchers will extract data from each paper. Studies 
will be categorised into IDEAL stages of study design 
from ‘pre-IDEAL’ to randomised controlled trials (stage 3). 
Data will be collected about the (1) novel intervention and 
criteria for modification, (2) governance arrangements 
and patient information provision, (3) outcome domains 
selected and reported and (4) quality of study design, 
conduct and reporting. Descriptive statistics and a 
narrative synthesis will be presented.
Ethics and dissemination The results of this systematic 
review will be presented at relevant conferences. The 
methods will be used to inform future reviews exploring 
other novel surgical innovations. The findings will be 
published in a peer-reviewed journal. This study does not 
require ethical approval.
IntroduCtIon
There is a need to improve outcomes for 
patients with oropharyngeal cancer. While 
surgery offers a chance of cure, it carries 
major risks, and there can be long-lasting 
detrimental effects on function and quality 
of life.1 Recent developments in treatment 
strategies have, therefore, been aimed at 
organ preservation as well as overall survival.2 
Such developments have included attenu-
ation in the field and dose of radiotherapy 
delivery and the introduction of innovative, 
less destructive surgical approaches including 
transoral laser and robotic techniques.
Transoral robotic surgery (TORS) is a tech-
nique first described in 2005 for the treatment 
of a benign pharyngeal cyst.3 It has since been 
applied to the resection of oropharyngeal 
cancers and the treatment of obstructive sleep 
apnoea, was approved by the Food and Drug 
Administration (FDA) for these indications 
in 2009 and was subsequently adopted into 
routine practice in several centres, particu-
larly in the USA.2 The National Health Service 
in England do not routinely commission 
TORS for the treatment of oropharyngeal 
or laryngeal cancer.4 The technique involves 
robotically assisted excision of a tumour or 
other tissue by an experienced surgeon who 
operates a control console in the same room 
but remote from the patient. Putative bene-
fits include less invasive surgical access, better 
in situ three-dimensional visualisation of the 
tumour, scaling of movement and elimina-
tion of hand tremor.5 Reported disadvantages 
include lack of tactile feedback and high 
cost.6 7 There appears, however, to be a lack 
of synthesised data about the effectiveness of 
strengths and limitations of this study
 ► This will be a comprehensive review of transoral 
robotic surgery and will track its innovative evolution 
since first published description to present day.
 ► Inclusion of all study types will allow identification 
of good and poor examples of the descriptions of 
innovative invasive procedures.
 ► The methods described are applicable to reviews of 
any innovative surgical or other invasive procedure.
 ► Lack of a sensitive literature search strategy may 
result in large numbers of abstracts to screen at the 
initial stages.
 ► Exclusion of papers not published in English may 
mean that important additional findings are missed.
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TORS. Factors associated with the development, evalua-
tion and implementation of this innovation have not yet 
been collated, described or summarised. The extent to 
which key issues around understanding surgical innova-
tions, including clinical indications for the innovation, 
which patients are offered the innovation, what informa-
tion is given to patients to ensure appropriate informed 
consent in the context of an innovative treatment (and 
within what governance structure), how the intervention 
is performed, which modifications are required during 
development (and what criteria inform decision to modify 
an intervention) and which outcomes and adverse events 
are reported in order to document known and potentially 
unknown consequences of new procedures have been 
considered also require clarification.
The Idea, Development, Exploration, Assessment, 
Long-term follow-up (IDEAL) framework was devel-
oped in 2009 and proposed a prospective, stepwise 
means of evaluating innovative procedures.8 9 It aims to 
help researchers and authors design and report studies 
of surgical innovation in a transparent way. Widespread 
adoption of the IDEAL framework by surgical innovators, 
researchers and journals has yet to be realised, and it is 
not known if the evolution of technologies such as TORS 
has been reported in accordance with this framework. 
An in-depth analysis of published literature on TORS will 
provide a case study of the reporting of a recently devel-
oped surgical intervention which is now offered as part of 
routine practice.
ovErAll objECtIvE
This study aims to systematically identify and comprehen-
sively summarise and critique studies reporting the intro-
duction, evolution and evaluation of TORS for obstructive 
sleep apnoea and oropharyngeal cancer.
specific research questions
The novel intervention and criteria for modification 
1. How is the novel intervention reported and criteria 
for modification described? 
2. How were patients selected to receive the interven-
tion? Did these criteria change over time? 
3. Were consecutive patients considered for eligibility to 
be offered the novel intervention? If not, were reasons 
provided? 
4. Were details of patients treated during the same time 
frame, and who did not receive the novel interven-
tion, reported (including reasons why they were not 
offered the new treatment, or whether they declined 
it and what treatment they did receive)? 
5. How was surgeon expertise/learning curve reported? 
6. Do the studies map onto the IDEAL stages of evalua-
tion of surgical innovation, and is there evidence that 
the IDEAL stage evolves over time? 
7. How are the novel intervention (TORS) and cointer-
ventions and/or comparators defined in the included 
studies? 
8. What is the overall quality of reporting of the includ-
ed studies as measured using validated tools for ran-
domised and non-randomised studies?
Governance arrangements 
9. How are ethical/governance considerations reported? 
For example, what descriptions of the process of ob-
taining the informed consent of patient participants 
are provided, if any? (note: the study protocols may 
be consulted in addition to the main report) 
10. Were patients informed about the innovative nature 
of the procedure?
Outcome domains reported 
11. Which clinical and patient-reported outcomes, and 
adverse events, are measured and reported in these 
studies? How are these outcomes defined and the 
time points for measurement selected? Did the stud-
ies report ‘failures’ as well as ‘successes’? 
12. Were outcomes relating to the operator and/or team 
reported? 
13. Which economic (eg, cost effectiveness) or other out-
comes relating to healthcare resource use (eg, oper-
ating time) were reported?
MEthods
Eligibility criteria
Studies will be included in the review if they meet the 
following inclusion criteria:
Participants
All patients (children and adults) being treated for benign 
or malignant oropharyngeal disease. In addition to clin-
ical studies, preclinical animal and cadaveric studies will 
be included for review so that the translation from these 
to first-in-human studies can be mapped.
Intervention
 ‘Transoral robotic surgery’ or ‘robotically assisted 
surgery’ or ‘robotic surgery for oropharyngeal cancer’ or 
‘robotic surgery for obstructive sleep apnoea’ or ‘robotic 
surgery for benign oropharyngeal disease’. Studies will 
not be limited to a single type, or manufacturer, of robot, 
or a particular technique.
Comparator(s)
 Alternative surgical approaches (eg, transoral laser 
surgery) and/or non-surgical treatments (eg, radio-
therapy and/or chemotherapy). It is anticipated that 
in certain types of early phase studies, there will be no 
comparator group.
Outcome(s)
 Clinical outcomes, patient-reported outcomes, adverse 
events, complications and early technical or process 
outcomes, reported criteria for modifying or withdrawing 
the intervention, resources use, cost and economic 
outcomes and reports of surgeons’ experiences of the 
new procedure (where documented).
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search strategy and study selection
Searches will be undertaken in OVID SP versions of 
Medline, and EMBASE, PubMed, SCOPUS, Web of 
Science, the Cochrane Central Register of Controlled 
Trials and the Cochrane Database of Systematic Reviews. 
The search strategy will be developed with the assistance 
of an information specialist. Search terms for TORS, 
surgery for oropharyngeal cancer, non-surgical treat-
ments of oropharyngeal cancer, surgery for obstruc-
tive sleep apnoea and benign oropharyngeal disease 
(including cysts and papillomas) will be combined using 
the Boolean ‘OR’ operator (online supplementary 
appendix 1). Preclinical (in vitro, animal and cadaveric) 
studies will be included only where they have been cited 
in a clinical study. The search will span from the start 
of indexing to 1 July 2017. Reference lists of included 
studies will be searched for additional references. Cita-
tions will be collated using Endnote reference manage-
ment software. Exclusion criteria will be (1) conference 
reports and abstracts and (2) studies of brain, skull base, 
lung, oral, hypopharyngeal, parapharyngeal, oesopha-
geal, thyroid, parathyroid, laryngeal, nasopharyngeal, 
eye, salivary gland or skin cancers.
Identification and selection of papers
A customised inclusion/exclusion form will be used 
to screen abstracts and to provide an audit trail. Titles 
and abstracts will be screened independently by three 
authors (BGM, AG and PR). Any conflicts not resolved 
by discussion between these authors will be referred to 
the study team for discussion. The full-text versions of 
papers retained after title and abstract screening will be 
downloaded for further assessment of their eligibility for 
inclusion. The review will be conducted in line with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist.10 A PRISMA flow 
diagram will be produced.
data extraction and management
Data will be extracted independently by at least two asses-
sors for each paper (BGM, JMB, NW, AG and PR). A 
customised data extraction form will be used to collect 
relevant data from each paper (online supplementary 
file). Data of interest will include:
The novel intervention and criteria for modification
1. author, date of publication, country of origin of 
study, journal of publication and rationale for the 
study;
2. details of any funding, including from robot manufac-
turers and/or other declared or potential conflicts of 
interest;
3. participant demographics (age, sex and tumour de-
tails);
4. details of the type of centre undertaking the inter-
vention, including any workload data reported. The 
number and grade of surgeon(s) operating, includ-
ing their experience with TORS (eg, training re-
ceived and evidence of preceptorship);
5. interventions, cointerventions, comparators and 
whether each was defined. Any definitions provided 
in the papers will be recorded verbatim;
6. in-depth details of any descriptions of the component 
parts of the intervention and any comparator (eg, ‘in-
cision’, ‘access’ and ‘dissection’)11 to explore if any 
specific components are subject to ongoing innova-
tion;
7. study classification using a modified IDEAL classifi-
cation tool. The original IDEAL framework does not 
come with guidance on how to apply it to the assess-
ment of studies already conducted and published.8 
An adaptation of the IDEAL framework has been de-
signed to permit its application to the retrospective 
analysis of published studies. It has been tested on a 
limited set of case studies, but is as yet unpublished.12 
This systematic review will use the new tool to analyse 
included studies and provide further pilot testing of 
its validity and reliability;
8. details of how the authors discuss and make con-
clusions related to their findings. For example, any 
descriptions of the need for further evaluation, the 
readiness of the intervention for adoption into rou-
tine practice or reasons for stopping the use of the 
intervention;
9. the overall quality of reporting will be assessed using 
an appropriate validated critical appraisal tool (eg, 
Consolidated Standards of Reporting Trials for ran-
domised controlled trials (RCTs)).13
Governance arrangements
10. information about governance approvals (ethics 
committee, Institutional Review Board (IRB), clin-
ical effectiveness committee approval, conformite 
Europeene (CE) mark approval, FDA approval and 
National Institute for Health and Care Excellence ap-
proval) and whether these approvals were for the de-
vice in general or its use for the treatment of specific 
clinical indications;
11. information about how informed consent was ob-
tained from patients, including whether or not they 
were informed about the innovative nature of the 
procedure (and if so, how? Eg, verbal or written 
information);
12. data about how many patients declined the 
intervention.
Outcome domains reported
13. names of individual outcomes reported and wheth-
er these were specified as primary or secondary 
outcomes;
14. definitions provided (if any) for each of the outcomes;
15. names of any patient-reported outcomes measures 
(PROMs);
16. the patient-reported outcome (PROs) will be classi-
fied and the scales used within each will be recorded. 
Any ad hoc, study-specific, non-validated PROMs will 
be documented;
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17. technical outcomes including issues such as intraop-
erative events and process outcomes relevant to the 
evaluation of innovative procedures;
18. cost and other economic outcomes.
Both randomised and non-randomised studies will be 
assessed for risk of bias using validated tools. RCTs will 
be assessed using the Cochrane Risk of Bias tool14 to 
assess the (1) adequacy of sequence generation, (2) allo-
cation concealment, (3) blinding of outcome assessors, 
(4) completeness of outcome data and (5) other sources 
of bias including selection and funding bias. Non-ran-
domised studies will be assessed using the Risk of Bias in 
Non-Randomised Studies of Interventions tool15 for bias 
due to: (1) confounding, (2) selection of participants into 
the study, (3) classification of interventions, (4) deviation 
from intended interventions, (5) missing data, (6) meas-
urement of outcomes and (7) selection of the reported 
result.
data syntheses and statistical analyses
Data will be entered into a custom database. Any discrep-
ancies in data extraction will be resolved by discussion 
with the entire study group.
The findings will be tabulated and, where appropriate, 
descriptive statistics performed. A narrative synthesis will 
summarise the findings of the review by organising data 
into descriptive themes. The analysis will be longitudinal 
(eg, does the IDEAL stage evolve over the time span of 
the review) and cross-sectional (eg, how do studies at 
a given time point differ?). This review will not aim to 
make conclusions about the relative effectiveness of 
TORS over other treatments for oropharyngeal cancer 
because the focus is on how innovative surgical proce-
dures are reported in the scientific literature. Therefore, 
no meta-analyses will be performed.
dIssEMInAtIon
The systematic review will be published in a peer-re-
viewed journal and presented at appropriate conferences 
(eg, methodological and surgical). This protocol will be 
adapted for the analysis of other innovative surgical and 
invasive procedures.
ConClusIon
This systematic review will provide important informa-
tion about the quality of studies of robotic surgery for 
oropharyngeal cancer and benign oropharyngeal disease. 
It will summarise the reporting of the novel intervention 
from early phase to any later phase studies published and 
available for review. It is intended to apply the methods 
described in this protocol to the analyses of reporting 
of other novel surgical interventions. The findings will 
inform further work that will aim to improve studies of 
innovative surgical interventions by setting standards for 
the conduct and reporting of both early and later phase 
trials .
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